Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Milojkovic D, et al. Among authors: shepherd p. Haematologica. 2010 Feb;95(2):224-31. doi: 10.3324/haematol.2009.012781. Epub 2009 Oct 14. Haematologica. 2010. PMID: 19833633 Free PMC article.
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Ibrahim AR, et al. Among authors: shepherd p. Haematologica. 2011 Dec;96(12):1779-82. doi: 10.3324/haematol.2011.049759. Epub 2011 Aug 22. Haematologica. 2011. PMID: 21859733 Free PMC article. Clinical Trial.
Not so NICE for CML.
Goldman J, Apperley J, Clark R, Green T, Holyoake T, O'Brien S, Shepherd P. Goldman J, et al. Among authors: shepherd p. Lancet. 2002 Jun 8;359(9322):2036. doi: 10.1016/S0140-6736(02)08796-2. Lancet. 2002. PMID: 12076575 No abstract available.
UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
Allan NC, Richards SM, Shepherd PC. Allan NC, et al. Among authors: shepherd pc. Lancet. 1995 Jun 3;345(8962):1392-7. doi: 10.1016/s0140-6736(95)92596-1. Lancet. 1995. PMID: 7760609 Clinical Trial.
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: shepherd pc. Blood. 2000 Jan 1;95(1):62-6. Blood. 2000. PMID: 10607685 Free article. Clinical Trial.
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.
Kluin-Nelemans HC, Buck G, le Cessie S, Richards S, Beverloo HB, Falkenburg JH, Littlewood T, Muus P, Bareford D, van der Lelie H, Green AR, Roozendaal KJ, Milne AE, Chapman CS, Shepherd P; MRC and HOVON groups. Kluin-Nelemans HC, et al. Among authors: shepherd p. Blood. 2004 Jun 15;103(12):4408-15. doi: 10.1182/blood-2003-10-3605. Epub 2004 Mar 9. Blood. 2004. PMID: 15010373 Free article. Clinical Trial.
363 results